当前位置: 首页 >> 检索结果
6224. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters.
作者: Dana V Wallace.;Mark S Dykewicz.;John Oppenheimer.;Jay M Portnoy.;David M Lang.
来源: Ann Intern Med. 2017年167卷12期876-881页
The Joint Task Force on Practice Parameters, which comprises representatives of the American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI), formed a workgroup to review evidence and provide guidance to health care providers on the initial pharmacologic treatment of seasonal allergic rhinitis in patients aged 12 years or older.
6226. Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings: A Systematic Review.
作者: Roger Chou.;P Todd Korthuis.;Dennis McCarty.;Phillip O Coffin.;Jessica C Griffin.;Cynthia Davis-O'Reilly.;Sara Grusing.;Mohamud Daya.
来源: Ann Intern Med. 2017年167卷12期867-875页
Naloxone is effective for reversing opioid overdose, but optimal strategies for out-of-hospital use are uncertain.
6228. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
作者: Lurdes Y T Inoue.;Daniel W Lin.;Lisa F Newcomb.;Amy S Leonardson.;Donna Ankerst.;Roman Gulati.;H Ballentine Carter.;Bruce J Trock.;Peter R Carroll.;Matthew R Cooperberg.;Janet E Cowan.;Laurence H Klotz.;Alexandre Mamedov.;David F Penson.;Ruth Etzioni.
来源: Ann Intern Med. 2018年168卷1期1-9页
Active surveillance (AS) is increasingly accepted for managing low-risk prostate cancer, yet there is no consensus about implementation. This lack of consensus is due in part to uncertainty about risks for disease progression, which have not been systematically compared or integrated across AS studies with variable surveillance protocols and dropout to active treatment.
6229. The Value-Based Payment Modifier: Program Outcomes and Implications for Disparities.
When risk adjustment is inadequate and incentives are weak, pay-for-performance programs, such as the Value-Based Payment Modifier (Value Modifier [VM]) implemented by the Centers for Medicare & Medicaid Services, may contribute to health care disparities without improving performance on average.
6230. Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.
作者: Philip E Castle.;Walter K Kinney.;Xiaonan Xue.;Li C Cheung.;Julia C Gage.;Fang-Hui Zhao.;Barbara Fetterman.;Nancy E Poitras.;Thomas S Lorey.;Nicolas Wentzensen.;Hormuzd A Katki.;Mark Schiffman.
来源: Ann Intern Med. 2018年168卷1期20-29页
Current U.S. cervical cancer screening and management guidelines do not consider previous screening history, because data on multiple-round human papillomavirus (HPV) and cytology "co-testing" have been unavailable.
6232. Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention.
作者: Winston E Abara.;Amir Qaseem.;Sarah Schillie.;Brian J McMahon.;Aaron M Harris.; .;George M Abraham.;Robert Centor.;Douglas M DeLong.;Heather E Gantzer.;Carrie A Horwitch.;Linda L Humphrey.;Janet A Jokela.;Joseph Ming Wah Li.;Robert H Lohr.;Ana María López.;Robert M McLean.
来源: Ann Intern Med. 2017年167卷11期794-804页
Vaccination, screening, and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection. However, recommendations vary among organizations, and their implementation has been suboptimal. The American College of Physicians' High Value Care Task Force and the Centers for Disease Control and Prevention developed this article to present best practice statements for hepatitis B vaccination, screening, and linkage to care.
6235. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California.
作者: Emanuel Krebs.;Benjamin Enns.;Elizabeth Evans.;Darren Urada.;M Douglas Anglin.;Richard A Rawson.;Yih-Ing Hser.;Bohdan Nosyk.
来源: Ann Intern Med. 2018年168卷1期10-19页
Only 1 in 5 of the nearly 2.4 million Americans with an opioid use disorder received treatment in 2015. Fewer than half of Californians who received treatment in 2014 received opioid agonist treatment (OAT), and regulations for admission to OAT in California are more stringent than federal regulations.
|